As leaders in hematologic oncology, stem cell & bone marrow transplantation, and immunotherapy, Duke Cancer Institute’s Hematologic Malignancies and Cellular Therapy (HMCT) group is internationally recognized for its novel approaches to treating leukemia, lymphoma, myeloma and other life threatening diseases.
Our Program’s mission is to promote health and improve lives by preventing, diagnosing, and treating these blood cancers through integrated, innovative, and holistic patient care, education, and research.
Duke Hematologic Malignancies & Cellular Therapy Specialists provide comprehensive, multidisciplinary care for patients at the Duke Cancer Center and the Duke Adult Blood & Marrow Transplant Clinic.
To make an appointment, please call 919.684.8964.
Providers who see patients in the Hematologic Malignancies Clinic include David Rizzieri, Carlos DeCastro, Joseph Moore, Thomas Leblanc, Matthew McKinney, Lindsay Rein, Ahmed Galal, and Alexandra Stefanovic.
Providers who see patients in the ABMT Clinic include Mitchell Horwitz, Nelson Chao, Gwynn Long, Cristina Gasparetto, Yubin Kang, Anthony Sung, Stefanie Sarantopoulos, Taewoong Choi, and Cristiana Costa.
The Duke Hematologic Malignancies & Cellular Therapy (HMCT) Program is a multidisciplinary basic, translational, and clinical research program whose overall goal is to improve outcomes for patients with hematologic malignancies.
Our research program can be broadly divided into the following research areas:
We offer our patients access to more than 50 active clinical trials specific to hematologic malignancies and transplantation.These trials range from securely storing your medical information in an outcomes-reporting registry, to sample repositories, and to national clinical trials and investigator-initiated trials designed to prevent, detect, or treat your underlying disease with the most advanced treatment methods. Your participation may help you and others in the future. Some of these trials are only offered at the Duke Cancer Institute. As a result, we offer a broad selection of treatment options to our patients, including some who are not considered candidates for treatment elsewhere. Your participation in a clinical trial may help you and others in the future.
Bringing Denial To Light
After two visits to a local ENT doctor who performed two biopsies – both benign – and then a follow-up visit to her primary care doctor, Joy Wood was at a crossroads. For the past six months she’d been troubled by itchy skin and odd lumps in her neck. Even after two benign biopsies, her primary care doctor wouldn’t rule out cancer. Insistent that she could not possibly have cancer, Wood found herself at odds with a doctor who now refused to move forward until she could substantiate her case. More
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More